Xiaojun Wang

Title: Innovations of Xiaojun Wang in Pharmaceutical Science

Introduction

Xiaojun Wang is a notable inventor based in Carmel, IN (US), recognized for his contributions to pharmaceutical science. He holds 2 patents that focus on innovative compounds and methods for treating various medical conditions. His work has significant implications for the development of new therapeutic options.

Latest Patents

One of Xiaojun Wang's latest patents is for sodium-hydrogen exchanger 3 (NHE3) inhibitor compounds. This invention relates to pharmaceutical compositions comprising the compound and its use for treating diseases associated with elevated sodium and/or phosphate levels. Another significant patent involves relaxin (RLN) analogs, which include modifications that enhance half-life compared to native human RLN. These analogs maintain selectivity to the RXFP1 receptor and provide improved stability for better druggability properties and reduced immunogenicity. The pharmaceutical compositions described in this patent include one or more RLN analogs in a pharmaceutically acceptable carrier, with methods for treating cardiovascular, pulmonary, and renal conditions.

Career Highlights

Xiaojun Wang is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to focus on innovative drug development, contributing to advancements in medical treatments.

Collaborations

Xiaojun collaborates with talented coworkers, including Petra Verdino and Stacey Lynn Lee, who contribute to the innovative environment at Eli Lilly and Company.

Conclusion

Xiaojun Wang's contributions to pharmaceutical science through his patents and work at Eli Lilly and Company highlight his role as an influential inventor in the field. His innovative approaches to drug development continue to pave the way for new therapeutic solutions.